Our Experts

Name: Liu Ji-hong
Title: Professor
Email: liujih@mail.sysu.edu.cn
Dr Ji-hong Liu is currently a professor of Gynecological Oncology Department (GO), as well as a supervisor of PhD student. Dr Liu obtained her MD and Master degree in Sun Yat-sen University of Medical Sciences, Guangzhou, China in 1984 and 1993, respectively. She then was granted a PhD degree in Sydney University, Australia in 2004. 

From 1997 to 2006, Dr Liu had been a vice chief of GO department and then since 2006, has become the director of this department. She had also been in charge of the administration of science research appointed as a vice-president of Sun Yat-sen University Cancer Center (SYSUCC) and a director of Clinical Study Center between 2004 and 2008. It was her responsibility for the establishment of Hospital Information System that gained her national prestige.

Dr Liu is an executive board member in Chinese Society of Gynecological Oncology and Gynecologic Oncology Committee of Chinese Anti-cancer Association; head of Guangdong GOG, vice president of Obstetrics and Gynecology sub-association, Guangdong Medical Association; president of Gynecologic Oncology Committee, Guangdong Anti-cancer Association.

In addition, Dr Liu is a reviewer or editorial board member for several academic Journals, including International Journal of Gynecologic Cancer, Chinese Journal of Cancer, Chinese Journal of Obstetrics and Gynecology, Chinese Journal of Medicine and so on. Dr Liu has been a practicing gynecological oncologist in SYSUCC for 30 years. In her general practice, she also actively initiated and participated in a number of clinical trials (national and international multi-center studies) and translational researches. 


human papillomavirus infection; 

molecular phenotype of ovarian carcinoma; 


lymph node metastasis of gynecological malignancies.

For information on Professor Liu's laboratory, click here and select: Molecular phenotypes and staging of ovarian carcinoma.

1984 1994 MD. Bacheler, Sun Yat-sen University of Medical Sciences, China.

1993 MSc. Master, Sun Yat-sen University of Medical Sciences, China.

2004 PhD, The University of Sydney, Australia


1. Shi Y, Li L, Hu Z, Li S, Wang S, Liu J (co-first author), etc. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nature Genetics. 2013; 45(8):918-22.

2. Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH(*). Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 2013; 60(5):546-52.

3. Lan C, Huang X, Cao X, Huang H, Feng Y, Huang Y, Liu J(*). Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a “sandwich” protocol in patients with advanced endometrial cancer: a single-institution experience. Expert Opin Pharmacother. 2013; 14(5):535-42.

4. Huang Q, Huang H, Wan T, Deng T, Liu J(*). Clinical outcome of 31 patients with primary malignant melanoma of the vagina. J Gynecol Oncol. 2013; 24(4):330-5.

5. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J(*). Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer. Technol Cancer Res Treat. 2013; 12(3):259-67.

6. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J, Liu J(*).High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 2013; 352(2):351-9.

7. Huang YW, Guan MF, Liu JH(*), Lan CY, Wan T, Huang X. Large animal model for retroperitoneal lymphatic and lung metastasis. Mol Med Rep. 2013; 8(6): 1617-22. 

8. Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, Huang H, Tu H, Jiang S, Zhang Y, Liu JH(*)& Song LB(*). Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012; 23(3):638-46.

9. Huang YW, Zeng Z, Li S, Liu JH(*). Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes. Tumour Biol. 2012; 33(6):2053-9.

10. Lan C, Huang X, Lin S, Cai M, Liu J(*). Endometrial Stromal Sarcoma Arising from Endometriosis: A Clinicopathological Study and Literature Review. Gynecol Obstet Invest 2012; 74:288-297.

11. Huang H, Li Y, Liu J(*), Zheng M, Feng Y, Hu K, Huang Y, Huang Q. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012; 7(12): e51256

12. Huang H, Liu J(*), Li Y, Wan T, Feng Y, Li Z, Huang Q. Metastasis to deep obturator and para-aortic lymph nodes in 649 patients with cervical carcinoma. Eur J Surg Oncol. 2011; 37(11):978-83.

13. Huang X, Lan CY, Huang HQ, Zhang YN, Huang H, Cao XP, Huang YW, Guo Y, Wan T, Liu JH(*). Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience. Expert Opin Pharmacother. 2011; 12(2):165-73

14. Huang L, Zheng M, Liu JH, Xiong Y, Ding H, Tang L, Wang HY. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. Chin J Cancer. 2010; 29(4):300-306

15. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, Wu HM, Kung HF, Zeng YX, Guan XY. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of eJF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecology Oncology. 2009; 112(2):314-318.

16. Liu JH, B Rose,Huang X, Liao GW, J Carter, Wu XJ, C Thompson , Comparative analysis of characteristics of women with cervical cancer in high- versus low- incidence regions. Gynecologic Oncology. 2004; 3(94):803-810


Last updated on: 2013

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.